Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer
Jérôme Cartry(Inserm), Fanny Jaulin(Inserm), David Malka(Inserm), Emilie Gontran(Inserm), Benjamin Besse(Institut Gustave Roussy), Mohamed Amine Bani(Institut Gustave Roussy), Maximiliano Gelli(Université Paris-Saclay), Isabelle Sourrouille(Institut Gustave Roussy), Peggy Dartigues(Institut Gustave Roussy), Maxime Annereau(Institut Gustave Roussy), Antoîne Italiano(Memorial Sloan Kettering Cancer Center), Alice Boilève(Institut Gustave Roussy), Bastien Job(Institut Gustave Roussy), Jacques R.R. Mathieu(Délégation Paris 5), Michel Ducreux(Université Paris-Saclay), Antoine Hollebecque(Institut Gustave Roussy), Ali Mouawia(Inserm), Pierre Mathias(Inserm), Cristina Smolenschi(Institut Gustave Roussy), Sabrina Bedja(Inserm), Thierry de Baère(Institut Gustave Roussy)
Cited by 47
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k